Your browser is no longer supported. Please, upgrade your browser.
Jazz Pharmaceuticals plc
Index- P/E19.09 EPS (ttm)9.11 Insider Own0.80% Shs Outstand56.47M Perf Week-0.84%
Market Cap10.60B Forward P/E9.72 EPS next Y17.90 Insider Trans-5.84% Shs Float55.44M Perf Month-1.72%
Income518.30M PEG1.37 EPS next Q3.50 Inst Own93.40% Short Float7.21% Perf Quarter4.32%
Sales2.44B P/S4.35 EPS this Y-53.60% Inst Trans1.92% Short Ratio5.94 Perf Half Y3.13%
Book/sh67.25 P/B2.59 EPS next Y23.05% ROA8.10% Target Price206.76 Perf Year53.91%
Cash/sh39.92 P/C4.36 EPS next 5Y13.93% ROE14.80% 52W Range107.59 - 189.00 Perf YTD5.38%
Dividend- P/FCF11.78 EPS past 5Y-4.20% ROI5.90% 52W High-7.97% Beta1.03
Dividend %- Quick Ratio4.10 Sales past 5Y12.30% Gross Margin93.40% 52W Low61.66% ATR4.07
Employees1940 Current Ratio4.20 Sales Q/Q13.60% Oper. Margin29.70% RSI (14)41.24 Volatility2.48% 2.09%
OptionableYes Debt/Eq0.55 EPS Q/Q174.00% Profit Margin21.30% Rel Volume0.49 Prev Close173.82
ShortableYes LT Debt/Eq0.49 EarningsAug 03 AMC Payout0.00% Avg Volume673.25K Price173.93
Recom1.70 SMA20-3.23% SMA50-2.79% SMA2006.23% Volume326,664 Change0.06%
May-19-21Resumed JP Morgan Overweight $183 → $206
Apr-07-21Resumed RBC Capital Mkts Outperform $186
Feb-05-21Reiterated H.C. Wainwright Buy $195 → $207
Feb-03-21Upgrade Piper Sandler Neutral → Overweight $150 → $175
Jan-29-21Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-16-20Initiated UBS Buy $174
Nov-03-20Reiterated H.C. Wainwright Buy $185 → $195
Oct-09-20Reiterated H.C. Wainwright Buy $175 → $185
Sep-14-20Resumed JP Morgan Overweight $175
Sep-14-20Downgrade Goldman Neutral → Sell $128
Aug-06-20Upgrade Morgan Stanley Equal-Weight → Overweight $177
Jul-28-20Upgrade Wolfe Research Peer Perform → Outperform
Jul-23-20Upgrade H.C. Wainwright Neutral → Buy
Apr-06-20Initiated Jefferies Buy $149
Mar-12-20Upgrade Bernstein Mkt Perform → Outperform $166
Jan-08-20Initiated Goldman Neutral $153
Aug-21-19Downgrade Piper Jaffray Overweight → Neutral $205 → $142
Jun-11-19Initiated Barclays Overweight $164
Mar-20-19Initiated SunTrust Buy $163
Dec-14-18Initiated Wolfe Research Peer Perform
Jul-25-21 05:42AM  
Jul-24-21 06:19AM  
Jul-22-21 04:15PM  
Jul-20-21 04:15PM  
Jul-16-21 02:08PM  
Jul-13-21 04:15PM  
Jul-07-21 10:15AM  
Jul-06-21 06:17PM  
Jul-05-21 05:30AM  
Jul-01-21 10:00AM  
Jun-30-21 08:04PM  
Jun-29-21 07:02AM  
Jun-28-21 03:48PM  
Jun-25-21 07:45AM  
Jun-22-21 10:09AM  
Jun-19-21 08:00PM  
Jun-17-21 08:33AM  
Jun-14-21 07:30AM  
Jun-09-21 07:45AM  
Jun-04-21 03:39PM  
Jun-03-21 11:31AM  
May-26-21 04:15PM  
May-20-21 07:45AM  
May-14-21 06:42AM  
May-11-21 10:35AM  
May-06-21 05:34AM  
May-05-21 04:54PM  
May-04-21 08:30PM  
Apr-29-21 04:05PM  
Apr-23-21 07:20PM  
Apr-22-21 04:30PM  
Apr-20-21 10:00AM  
Apr-19-21 04:05PM  
Apr-16-21 02:08PM  
Apr-14-21 12:04PM  
Apr-13-21 09:33AM  
Apr-12-21 07:45AM  
Apr-09-21 05:47PM  
Apr-05-21 06:00AM  
Mar-31-21 09:59AM  
Mar-30-21 06:15PM  
Mar-25-21 11:30AM  
Mar-23-21 10:18AM  
Mar-22-21 04:05PM  
Mar-18-21 08:05AM  
Mar-17-21 04:08AM  
Mar-11-21 06:25AM  
Mar-05-21 10:00AM  
Feb-24-21 06:00AM  
Feb-23-21 10:00PM  
Feb-22-21 10:21AM  
Feb-17-21 04:05PM  
Feb-16-21 09:11PM  
Feb-15-21 01:25AM  
Feb-12-21 06:55AM  
Feb-11-21 11:29AM  
Feb-10-21 11:57AM  
Feb-09-21 04:05PM  
Feb-08-21 10:41AM  
Feb-07-21 12:00PM  
Feb-06-21 06:30AM  
Feb-05-21 04:21PM  
Feb-04-21 10:10AM  
Feb-03-21 07:03PM  
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOJul 01Sale180.6710,8501,960,269308,888Jul 06 06:27 PM
COZADD BRUCE CChairman & CEOJun 01Sale179.071,750313,372319,738Jun 03 05:17 PM
COZADD BRUCE CChairman & CEOMay 05Sale170.0050085,000321,341May 05 07:03 PM
COZADD BRUCE CChairman & CEOMay 03Sale164.241,500246,360321,841May 05 07:03 PM
COZADD BRUCE CChairman & CEOApr 01Sale164.961,500247,440323,341Apr 06 06:13 PM
Carr PatriciaVP, Finance & PAOMar 09Sale161.50961155,2026,045Mar 10 04:25 PM
Carr PatriciaVP, Finance & PAOMar 08Sale161.611,089175,9887,006Mar 10 04:25 PM
Larkin FinbarSVP, Technical OperationsMar 08Sale161.601,509243,85916,519Mar 10 04:27 PM
COZADD BRUCE CChairman & CEOMar 01Sale170.009,6001,632,000346,357Mar 03 04:27 PM
COZADD BRUCE CChairman & CEOFeb 03Sale160.0025040,000318,032Feb 03 06:00 PM
COZADD BRUCE CChairman & CEOFeb 01Sale156.151,250195,188318,282Feb 03 06:00 PM
COZADD BRUCE CChairman & CEOJan 04Sale162.017,9501,287,980319,532Jan 06 04:35 PM
Carr PatriciaVP, Finance & PAODec 04Sale152.55629,4586,200Dec 08 05:09 PM
COZADD BRUCE CChairman & CEODec 03Sale150.0025037,500327,482Dec 03 04:26 PM
COZADD BRUCE CChairman & CEODec 01Sale140.581,000140,580327,732Dec 03 04:26 PM
ENRIGHT PATRICK GDirectorNov 12Sale146.729,9291,456,73820,368Nov 13 04:56 PM
Larkin FinbarSVP, Technical OperationsNov 06Sale151.9319729,93013,964Nov 10 06:16 PM
O'Keefe Kenneth WDirectorNov 05Sale154.8611,0001,703,42118,667Nov 09 04:53 PM
Sohn Catherine A.DirectorNov 04Option Exercise59.4012,500742,56018,622Nov 06 04:42 PM
Sohn Catherine A.DirectorNov 04Sale153.4412,5001,918,00010,622Nov 06 04:42 PM
BERNS PAUL LDirectorNov 04Sale150.424,691705,6049,740Nov 04 07:33 PM
COZADD BRUCE CChairman & CEONov 03Sale154.002,500385,000328,680Nov 04 07:24 PM
COZADD BRUCE CChairman & CEONov 02Sale145.131,000145,130331,180Nov 04 07:24 PM
COZADD BRUCE CChairman & CEOOct 01Sale141.944,500638,730332,180Oct 05 07:21 PM
Larkin FinbarSVP, Technical OperationsSep 09Sale138.53638,72714,161Sep 10 06:48 PM
COZADD BRUCE CChairman & CEOSep 01Sale134.9050067,450336,680Sep 03 04:49 PM
COZADD BRUCE CChairman & CEOAug 27Sale130.003,000390,000337,180Aug 31 05:45 PM
Carr PatriciaVP, Finance & PAOAug 12Sale123.8014217,5806,200Aug 14 05:33 PM
Carr PatriciaVP, Finance & PAOAug 07Sale125.8715819,8876,342Aug 11 07:51 PM
Winningham Rick EDirectorAug 07Sale125.87931117,1856,198Aug 10 04:57 PM
Sohn Catherine A.DirectorAug 07Sale125.87931117,18610,622Aug 10 04:54 PM
RIEDEL NORBERT GDirectorAug 07Sale125.87931117,1869,459Aug 10 04:50 PM
O'Keefe Kenneth WDirectorAug 07Sale125.87931117,1867,418Aug 10 04:48 PM
McSharry Heather AnnDirectorAug 07Sale125.871,009127,00310,333Aug 10 04:45 PM
BERNS PAUL LDirectorAug 07Sale125.87931117,1859,740Aug 10 04:40 PM